Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.

Yin X, Yin Y, Shen C, Chen H, Wang J, Cai Z, Chen Z, Zhang B.

Onco Targets Ther. 2018 Oct 2;11:6405-6414. doi: 10.2147/OTT.S156760. eCollection 2018.

2.

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.

Belum VR, Wu S, Lacouture ME.

Invest New Drugs. 2013 Aug;31(4):1078-86. doi: 10.1007/s10637-013-9977-0. Epub 2013 May 23.

PMID:
23700287
3.

Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.

Wang Z, Xu J, Nie W, Huang G, Tang J, Guan X.

Eur J Clin Pharmacol. 2014 Feb;70(2):225-31. doi: 10.1007/s00228-013-1598-1. Epub 2013 Oct 23. Review.

PMID:
24150533
4.

Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.

Crona DJ, Keisler MD, Walko CM.

Ann Pharmacother. 2013 Dec;47(12):1685-96. doi: 10.1177/1060028013509792. Epub 2013 Nov 1. Review.

PMID:
24259629
5.

Incidence and risk of regorafenib-induced hepatotoxicity.

Zhao B, Zhao H.

Oncotarget. 2017 Sep 20;8(48):84102-84111. doi: 10.18632/oncotarget.21106. eCollection 2017 Oct 13.

6.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Nishijima TF, Shachar SS, Nyrop KA, Muss HB.

Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8. Review.

7.

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.

Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T.

Int J Clin Oncol. 2015 Oct;20(5):905-12. doi: 10.1007/s10147-015-0790-y. Epub 2015 Feb 6.

8.

Prevention and management of adverse events related to regorafenib.

De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A, Cremolini C.

Support Care Cancer. 2014 Mar;22(3):837-46. doi: 10.1007/s00520-013-2085-z. Epub 2013 Dec 14. Review.

9.

Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Luo W, Wang Z, Tian P, Li W.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1851-1859. doi: 10.1007/s00432-018-2707-4. Epub 2018 Jul 17. Review.

PMID:
30019319
10.

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E.

Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Review.

11.

Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.

Cao M, Li F, Wang Y, Zhang J.

Invest New Drugs. 2017 Dec;35(6):834-838. doi: 10.1007/s10637-017-0512-6. Epub 2017 Sep 22. Review.

PMID:
28936569
12.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A.

Oncologist. 2018 Sep 6. pii: theoncologist.2018-0072. doi: 10.1634/theoncologist.2018-0072. [Epub ahead of print]

PMID:
30190299
13.

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.

Cochrane Database Syst Rev. 2014 Oct 23;(10):CD007744. doi: 10.1002/14651858.CD007744.pub2. Review.

PMID:
25340915
14.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N.

Lancet Oncol. 2016 Dec;17(12):1732-1742. doi: 10.1016/S1470-2045(16)30507-1. Epub 2016 Oct 14.

PMID:
27751846
15.

Natalizumab for induction of remission in Crohn's disease.

Nelson SM, Nguyen TM, McDonald JW, MacDonald JK.

Cochrane Database Syst Rev. 2018 Aug 1;8:CD006097. doi: 10.1002/14651858.CD006097.pub3. Review.

PMID:
30068022
16.

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O.

Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15.

17.

Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.

Zhu Y, Zhang X, Lou X, Chen M, Luo P, He Q.

Clin Exp Pharmacol Physiol. 2018 Jul;45(7):659-667. doi: 10.1111/1440-1681.12935. Epub 2018 Apr 25.

18.

Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.

Belum VR, Serna-Tamayo C, Wu S, Lacouture ME.

Clin Exp Dermatol. 2016 Jan;41(1):8-15. doi: 10.1111/ced.12694. Epub 2015 May 25. Review.

19.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD.

Oncologist. 2014 Jun;19(6):669-80. doi: 10.1634/theoncologist.2013-0059. Epub 2014 May 12.

20.

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.

Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL.

Cancer Treat Rev. 2018 Jan;62:61-73. doi: 10.1016/j.ctrv.2017.10.011. Epub 2017 Nov 10. Review.

PMID:
29175677

Supplemental Content

Support Center